Clinical-stage biotech stocks carry significant risks, but also offer explosive upside potential. These companies are built ...

Both patients with IPF and patients with PPF treated with nerandomilast demonstrated a smaller decline in forced vital ...

Chinese scientists have developed a novel nanotherapy known as biomimetic extracellular vesicle spherical nucleic acids (BEV-SNAs), which has shown efficacy in treating idiopathic pulmonary fibrosis ...

A novel medication out of Sweden has shown some of the same promise in melting belly fat — without making your stomach churn.

A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase 2 clinical trial.

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly one-quarter of their body weight in early trials.

ProPublica spent 14 months investigating the FDA’s oversight of foreign drugmakers that send medications to the U.S. These are the key takeaways.

The global progressive pulmonary fibrosis (PPF) treatment market is projected to be valued at USD 4,044.6 Million in 2025 and is expected to reach USD 8,182.4 Million by 2035, registering a CAGR of 7.

Trump’s most-favored-nation executive order would collapse the American pharmaceutical industry’s innovation edge.

A new study suggests that a medication in the same family as Ozempic could cut the number of days people suffer from migraines by more than half.

Gilead’s twice-a-year HIV prevention drug lenacapavir is 30 years in the making. Here’s the story behind it.

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new challenger to blockbusters from Novo Nordisk A/S and Eli Lilly & Co.